Eighteen CRC tumor cultures were from NSCLC specimens with a total of 22 known oncogene mutations such as KRAS, EGFR, PTEN, TP53 or ALK rearrangements demonstrated in the primary tumor specimens at diagnosis (Supplementary Table S1). This evidence concerns the gene KRAS and non-small cell lung carcinoma.